An observational study in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease, sponsored by Schön Klinik Berchtesgadener Land. Completed at 1 site in Germany. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-30.
Sponsored by Schön Klinik Berchtesgadener Land · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Idiopathic Pulmonary Fibrosis with a site in Germany — 10 open to participants now, 15 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · Germany.
Among the 76 studies in Idiopathic Pulmonary Fibrosis with a site in Germany, this one is one of 4 that started in 2020, is one of 8 observational ones, and was the 40th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →10 of the 76 studies in Idiopathic Pulmonary Fibrosis with a site in Germany are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United States, Argentina and 20 more countries
Ages 40+
Avalyn Pharma Inc. · Sites in Germany, Australia, Canada and 4 more countries
Ages 40+
Rein Therapeutics · Sites in Germany, United States, Australia and 4 more countries
Ages 40+
AbbVie · Sites in Germany, United States, Australia and 14 more countries
Ages 40+
Contineum Therapeutics · Sites in Germany, Argentina, Australia and 16 more countries
Ages 40+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 37 · Phase 3 17 · Phase 4 4
First in 2000; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 152 across 165 observational studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 163 across the 68 interventional studies, 150 across the 8 observational. Of the 59 that completed or were terminated, 38 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 76 have an industry lead sponsor. The 10 most frequent:
Schön Klinik Berchtesgadener Land is the lead sponsor of 51 studies on the registry; 2 are open to participants now.
Schön Klinik Berchtesgadener Land has 5 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Idiopathic Pulmonary Fibrosis with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT07194382Avalyn Pharma Inc.AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF | 2026-12 |
| NCT07036523Boehringer IngelheimA Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment | 2027-03-11 |
| NCT06588686Vicore Pharma ABA Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. | 2027-05 |
| NCT06968845Rein TherapeuticsA Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 76 studies in Idiopathic Pulmonary Fibrosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this prospective observational trial is to evaluate the influence of Coping strategies on pulmonary rehabilitation outcomes like 6-minute walk distance and Quality of life.
In the recent pulmonary rehabilitation (PR) statement of the American Thoracic Society/ European Respiratory Society, PR is mentioned to be beneficial by improving exercise capacity, symptoms and quality of life in patients with other chronic respiratory diseases than chronic obstructive pulmonary disease (COPD) (1). Although patients with idiopathic pulmonary fibrosis (IPF) often suffer from psychological distress such as symptoms of anxiety and depression, only little is known about the impact of these mental co-morbidities on PR outcomes.
In a former study the investigators demonstrated that patients with IPF benefit well from an inpatient PR program of only 3 weeks duration by improving exercise capacity (6-Minute walk distance), health-related quality of life as well as symptoms of anxiety and depression. During the 3-months follow-up after PR, most of these improvements disappeared so that this group showed similar values at follow-up compared to baseline. However, in contrast patients from the control-group with usual care worsened significantly during the 6 months study period.
Interestingly, a linear regression analysis revealed that IPF patients with lower levels of anxiety showed the tendency to have the best sustainability in exercise capacity at the 3 months follow-up. Given that maintenance of exercise capacity may be crucial to influence prognosis and the risk of mortality, reducing symptoms of anxiety might be of special interest.
The negative influence of anxiety symptoms on exercise capacity is a new finding in IPF patients but already known in the field of other chronic diseases: in patients with chronic pain and recently also in patients with COPD, "fear avoidance" behavior is discussed as having a direct negative influence on daily physical activity levels. COPD patients seem to develop fear/anxiety of exercise-related dyspnea due to classical and operant conditioning. This may lead to consecutive avoidance of physical activity and other exercises in daily life (2).
Anxiety symptoms and psychological distress have been shown to be related to patients individual illness perceptions and their way of coping with the disease like e.g. problem-focusing coping, looking for information, depressive coping.
In patients with IPF, the role of coping styles in the context of PR has not been investigated yet. It is unclear whether anxiety symptoms are influenced by individual characteristics of IPF patients such as specific coping strategies and illness perceptions and therefore, whether individual coping strategies might have an influence on the PR outcome.
This latter might be an underestimated issue influencing the PR effects in patients with chronic respiratory diseases. Better knowledge in this field is of special clinical importance in order to ensure short- und long term PR success. Potential differences in psychological profiles or coping strategies between COPD and IPF patients might result in disease-specific interventions during and after PR.
Therforme, aim of this study is to evaluate the influence of coping strategies on pulmonary rehabilitation outcomes.
This study is a prospective observational trial. Asssessments will take place at admission of the rehabilitation program, at discharge and partially after 3-month.
Patients who take part in a pulmonary rehabilitation program at Schoen Klinik Berchtesgadener land will recruited.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Coping strategies in anxious vs. non-anxious IPF-patients
Difference in Essener Coping questionnaire in axious (Hospital anxiety and Depression scale \[HADS\]\>=8points) and non-anxious (HADS\<8points) IPF-patients
Time frame: Day 1, Day 21 and 3-months after pulmonary rehabilitation program (Day 21)
Correlation between 6-minute walk distance and Essener Coping questionnaire
The essener Coping questionnaire measures coping mechanisms; a 45-item self-report questionnaire; higher scores indicate higher presence of the respective state
Time frame: Day 1 and Day 21
Correlation between Health related Quality of life and Essener Coping questionnaire
Health related Quality of life will be assessed by chronic respiratory disease questionnaire (CRQ)- a 20-item self-report questionnaire; score 1-7; higher scores indicate a better health-related quality of life ; The essener Coping questionnaire measures coping mechanisms; a 45-item self-report questionnaire; higher scores indicate higher presence of the respective state
Time frame: Day 1, Day 21 and 3-months after pulmonary rehabilitation program
Correlation between 6-minute walk distance and Hospital Anxiety and Depresion scale
Anxiety/Depression measured by Hospital Anxiety and Depression Scale (HADS) - a screening questionnaire including 6 questions about depression and 8 questions about anxiety; higher scores indicate higher presence of anxiety/ depression
Time frame: Day 1 and Day 21
Correlation between 6-minute walk distance and COPD anxiety questionnaire
assessed by the German "COPD Angst Fragebogen" (CAF) - a 20-item self-report questionnaire, rated on a Lickert-scale (score 0-4); maximum score: 80 points; higher scores indicate higher anxiety levels.
Time frame: Day 1 and Day 21
Correlation between 6-minute walk distance and Illness Perception Questionnaire
assessed by the Illness perception Questionnaire, revised (IPQ-R) - 18 items, score 1-5; higher scores indicate a worse illness perception, except of item 7,9,10,11,12.
Time frame: Day 1 and Day 21
Correlation between 6-minute walk distance and Patient-Health questionnaire
Depression measured by Patient-Health questionnaire including 9 items; each question range from 0 to 3; higher scores indicate higher presence of the respective state
Time frame: Day 1 and Day 21
Correlation between 6-minute walk distance and Health related Quality of life
Health related Quality of life will be assessed by chronic respiratory disease questionnaire (CRQ)- a 20-item self-report questionnaire; score 1-7; higher scores indicate a better health-related quality of life
Time frame: Day 1 and Day 21
Correlation between 6-minute walk distance and SF-36 survey
Health related quality of life will be measured by SF-36 questionnaire; a screening questionnaire including 36-items; higher score indicate higher quality of life
Time frame: Day 1 and Day 21
Correlation between 6-minute walk distance and King´s Brief Interstitial lung disease questionnaire
Health Status measured by King's Brief Interstitial lung disease questionnaire including 15 items; higher scores indicate better respective state
Time frame: Day 1 and Day 21
Correlation between physical activity level and Essener Coping questionnaire
The essener Coping questionnaire measures coping mechanisms; a 45-item self-report questionnaire; higher scores indicate higher presence of the respective state
Time frame: 2 weeks and 3 months after pulmonary rehabilitation program completion (Day 21) activity monitoring for 5 week days each
Correlation between physical activity level and Hospital Anxiety and Depresion scale
Anxiety/Depression measured by Hospital Anxiety and Depression Scale (HADS) - a screening questionnaire including 6 questions about depression and 8 questions about anxiety; higher scores indicate higher presence of anxiety/ depression
Time frame: 2 weeks and 3 months after pulmonary rehabilitation program completion (Day 21) activity monitoring for 5 week days each
Correlation between physical activity level and COPD anxiety questionnaire
assessed by the German "COPD Angst Fragebogen" (CAF) - a 20-item self-report questionnaire, rated on a Lickert-scale (score 0-4); maximum score: 80 points; higher scores indicate higher anxiety levels.
Time frame: 2 weeks and 3 months after pulmonary rehabilitation program completion (Day 21) activity monitoring for 5 week days each
Correlation between physical activity level and Illness Perception Questionnaire
assessed by the Illness perception Questionnaire, revised (IPQ-R) - 18 items, score 1-5; higher scores indicate a worse illness perception, except of item 7,9,10,11,12.
Time frame: 2 weeks and 3 months after pulmonary rehabilitation program completion (Day 21) activity monitoring for 5 week days each
Correlation between physical activity level and Patient-Health questionnaire
Depression measured by Patient-Health questionnaire including 9 items; each question range from 0 to 3; higher scores indicate higher presence of the respective state
Time frame: 2 weeks and 3 months after pulmonary rehabilitation program completion (Day 21) activity monitoring for 5 week days each
Correlation between physical activity level and chronic respiratory disease questionnaire
Depression measured by Patient-Health questionnaire including 9 Items; each question range from 0 to 3; higher scores indicate higher presence of the respective state
Time frame: 2 weeks and 3 months after pulmonary rehabilitation program completion (Day 21) activity monitoring for 5 week days each
Correlation between physical activity level and SF-36 survey
Health related quality of life will be measured by SF-36 questionnaire; a screening questionnaire including 36-items; higher score indicate higher quality of life
Time frame: 2 weeks and 3 months after pulmonary rehabilitation program completion (Day 21) activity monitoring for 5 week days each
Correlation between physical activity Level and King´s Brief Interstitial lung disease questionnaire
Health Status measured by King's Brief Interstitial lung disease questionnaire including 15 items; higher scores indicate better respective state
Time frame: 2 weeks and 3 months after pulmonary rehabilitation program completion (Day 21) activity monitoring for 5 week days each
Differences in Coping mechanisms between IPF and COPD patients
The essener Coping questionnaire measures coping mechanisms; a 45-item self-report questionnaire; higher scores indicate higher presence of the respective state
Time frame: Day 1, Day 21 and 3-months after pulmonary rehabilitation program (Day 21)
Ran from Feb 2020 to primary completion in Dec 2024, 58 months.
Of 74 non-industry observational studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 102. This study's 58 months is close to that.
Counting every sponsor, half of 88 studies reached it within 51 months; a quarter within 29 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idiopathic Pulmonary Fibrosis →
Schön Klinik Berchtesgadener Land